



Innovations in Early Cancer Diagnostics and Therapeutics

Guest Editors:

Dr. Seddik Hammad

Molecular Hepatology Section,
Department of Medicine II,
Medical Faculty Mannheim,
University of Heidelberg,
Mannheim, Germany

Dr. Mohamed Bekheit

Institute of Medical Sciences,
University of Aberdeen,
Aberdeen, UK

Deadline for manuscript
submissions:

closed (15 May 2023)

Message from the Guest Editors

Many cancers can be cured if detected/diagnosed early and treated effectively; however, they are mostly diagnosed at advanced stages when systemic therapies are indicated. Therefore, preclinical studies are required and should be coupled with clinical investigations to identify a robust and reliable method for identifying/diagnosing patients in the very early stages of cancer development. Not only prognostic/diagnostic values, but also the targets can be used to combat the disease development, progression and metastasis. Authors are invited to submit manuscripts that delineate these cancer-assigned prognostic, diagnostic and therapeutic targets (pathways). Data may provide useful information and clinical rationale concerning how to better and more accurately diagnose human cancers with the goal to foster therapeutic interventions.

We welcome experts in the field to contribute research papers and critical reviews regarding the various facets of preclinical to clinical investigations that modulate cancer development and progression, as well as on how natural and pharmacological pathways may be exploited as tools in anticancer therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)